Cadus Announces Delisting From Nasdaq National Market.NEW YORK--(BUSINESS WIRE)--Sept. 24, 1999-- Cadus Pharmaceutical Corporation (Nasdaq: KDUS) announced today that, as a result of the Company no longer meeting the requirements for continued listing, the Company's common stock will be removed from listing on the Nasdaq National Market effective as of the opening of business on Monday, September 27, 1999. Beginning on that date, the Company's common stock will be traded on the OTC Bulletin Board OTC Bulletin Board An electronic quotation listing of the bid and asked prices of OTC stocks that do not meet the requirements to be listed on the NASDAQ stock-listing system. under the symbol KDUS. This press release may contain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company's prospectus dated July 17, 1996 or detailed from time to time in filings that the company makes with the Securities and Exchange Commission. These include risks and uncertainties relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc the company's ongoing litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. with SIBIA Neurosciences, Inc. ("SIBIA"), including uncertainties regarding the outcome of appeals and the re-examination RE-EXAMINATION. A second examination of a thing. A witness maybe reexamined, in a trial at law, in the discretion of the court, and this is seldom refused. In equity, it is a general rule that there can be no reexamination of a witness, after he has once signed his name to the deposition, of SIBIA's patent at issue in the litigation, risks and uncertainties relating to the company's ability to realize value from its assets, technological uncertainties regarding the company's technology, rapid technological change, an intensely competitive market, intellectual property rights and general economic conditions. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion